Publication
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (12)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 12
- cancerMalignant Endometrial Neoplasmcivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- cancerTransitional Cell Carcinomacivic_curation1.00
- drugErdafitinibcivic_curation1.00
- geneBICC1civic_curation1.00
- geneCCDC6civic_curation1.00
- geneFGFR2civic_curation1.00
- geneTACC3civic_curation1.00
- variantBICC1 Fusioncivic_curation1.00
- variantCCDC6 Fusioncivic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
- variantTACC3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26324363
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BICC1 Fusion2 | ||||||||
| Erdafitinib | Malignant Endometrial NeoplasmCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1920Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC | civic |
| 〃 | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1917Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberratio… (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC | civic |
| FGFR2 Fusion1 | ||||||||
| Erdafitinib | Malignant NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1918Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC | civic |
| TACC3 Fusion1 | ||||||||
| Erdafitinib | Malignant NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1919Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC | civic |
| CCDC6 Fusion + TACC3 FusionTACC3CCDC61 | ||||||||
| Erdafitinib | Adrenal CarcinomaUNRESOLVED | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID4861Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC | civic |